436 related articles for article (PubMed ID: 26044126)
21. Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease.
Banales JM; Masyuk TV; Bogert PS; Huang BQ; Gradilone SA; Lee SO; Stroope AJ; Masyuk AI; Medina JF; LaRusso NF
Am J Pathol; 2008 Dec; 173(6):1637-46. PubMed ID: 18988797
[TBL] [Abstract][Full Text] [Related]
22. Ca2+-dependent cytoprotective effects of ursodeoxycholic and tauroursodeoxycholic acid on the biliary epithelium in a rat model of cholestasis and loss of bile ducts.
Marzioni M; Francis H; Benedetti A; Ueno Y; Fava G; Venter J; Reichenbach R; Mancino MG; Summers R; Alpini G; Glaser S
Am J Pathol; 2006 Feb; 168(2):398-409. PubMed ID: 16436655
[TBL] [Abstract][Full Text] [Related]
23. Ursodeoxycholic acid protects concanavalin A-induced mouse liver injury through inhibition of intrahepatic tumor necrosis factor-alpha and macrophage inflammatory protein-2 production.
Ishizaki K; Iwaki T; Kinoshita S; Koyama M; Fukunari A; Tanaka H; Tsurufuji M; Sakata K; Maeda Y; Imada T; Chiba K
Eur J Pharmacol; 2008 Jan; 578(1):57-64. PubMed ID: 17888421
[TBL] [Abstract][Full Text] [Related]
24. Use of ursodeoxycholic acid in patients with liver disease.
Angulo P
Curr Gastroenterol Rep; 2002 Feb; 4(1):37-44. PubMed ID: 11825540
[TBL] [Abstract][Full Text] [Related]
25. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited.
Paumgartner G; Beuers U
Hepatology; 2002 Sep; 36(3):525-31. PubMed ID: 12198643
[TBL] [Abstract][Full Text] [Related]
26. Ursodeoxycholate inhibits mast cell activation and reverses biliary injury and fibrosis in Mdr2
Meng F; Kennedy L; Hargrove L; Demieville J; Jones H; Madeka T; Karstens A; Chappell K; Alpini G; Sybenga A; Invernizzi P; Bernuzzi F; DeMorrow S; Francis H
Lab Invest; 2018 Nov; 98(11):1465-1477. PubMed ID: 30143751
[TBL] [Abstract][Full Text] [Related]
27. Ursodeoxycholic Acid for Treatment of Enlarged Polycystic Liver.
Iijima T; Hoshino J; Suwabe T; Sumida K; Mise K; Kawada M; Imafuku A; Hayami N; Hiramatsu R; Hasegawa E; Sawa N; Takaichi K; Ubara Y
Ther Apher Dial; 2016 Feb; 20(1):73-8. PubMed ID: 26482029
[TBL] [Abstract][Full Text] [Related]
28. The effect of ursodeoxycholic acid on oxidative stress level and DNase activity in rat liver after bile duct ligation.
Sokolovic D; Nikolic J; Kocic G; Jevtovic-Stoimenov T; Veljkovic A; Stojanovic M; Stanojkovic Z; Sokolovic DM; Jelic M
Drug Chem Toxicol; 2013 Apr; 36(2):141-8. PubMed ID: 22385135
[TBL] [Abstract][Full Text] [Related]
29. Autophagy-mediated reduction of miR-345 contributes to hepatic cystogenesis in polycystic liver disease.
Masyuk T; Masyuk A; Trussoni C; Howard B; Ding J; Huang B; LaRusso N
JHEP Rep; 2021 Oct; 3(5):100345. PubMed ID: 34568801
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic Targets in Polycystic Liver Disease.
Masyuk TV; Masyuk AI; LaRusso NF
Curr Drug Targets; 2017; 18(8):950-957. PubMed ID: 25915482
[TBL] [Abstract][Full Text] [Related]
31. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease.
Lindblad A; Glaumann H; Strandvik B
Hepatology; 1998 Jan; 27(1):166-74. PubMed ID: 9425933
[TBL] [Abstract][Full Text] [Related]
32. Oxidative stress and apoptosis in fetal rat liver induced by maternal cholestasis. Protective effect of ursodeoxycholic acid.
Perez MJ; Macias RI; Duran C; Monte MJ; Gonzalez-Buitrago JM; Marin JJ
J Hepatol; 2005 Aug; 43(2):324-32. PubMed ID: 15970352
[TBL] [Abstract][Full Text] [Related]
33. Protective effects of ursodeoxycholic acid on chenodeoxycholic acid-induced liver injury in hamsters.
Iwaki T; Ishizaki K; Kinoshita S; Tanaka H; Fukunari A; Tsurufuji M; Imada T
World J Gastroenterol; 2007 Oct; 13(37):5003-8. PubMed ID: 17854144
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease.
Lee SO; Masyuk T; Splinter P; Banales JM; Masyuk A; Stroope A; Larusso N
J Clin Invest; 2008 Nov; 118(11):3714-24. PubMed ID: 18949056
[TBL] [Abstract][Full Text] [Related]
35. Ursodeoxycholate modulates bile flow and bile salt pool independently from the cystic fibrosis transmembrane regulator (Cftr) in mice.
Bodewes FA; Wouthuyzen-Bakker M; Bijvelds MJ; Havinga R; de Jonge HR; Verkade HJ
Am J Physiol Gastrointest Liver Physiol; 2012 May; 302(9):G1035-42. PubMed ID: 22301109
[TBL] [Abstract][Full Text] [Related]
36. Biliary secretion of S-nitrosoglutathione is involved in the hypercholeresis induced by ursodeoxycholic acid in the normal rat.
Rodríguez-Ortigosa CM; Banales JM; Olivas I; Uriarte I; Marín JJ; Corrales FJ; Medina JF; Prieto J
Hepatology; 2010 Aug; 52(2):667-77. PubMed ID: 20683964
[TBL] [Abstract][Full Text] [Related]
37. Clinical efficacy and effectiveness of ursodeoxycholic acid in cholestatic liver diseases.
Festi D; Montagnani M; Azzaroli F; Lodato F; Mazzella G; Roda A; Di Biase AR; Roda E; Simoni P; Colecchia A
Curr Clin Pharmacol; 2007 May; 2(2):155-77. PubMed ID: 18690863
[TBL] [Abstract][Full Text] [Related]
38. Telmisartan ameliorates fibrocystic liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease.
Yoshihara D; Kugita M; Sasaki M; Horie S; Nakanishi K; Abe T; Aukema HM; Yamaguchi T; Nagao S
PLoS One; 2013; 8(12):e81480. PubMed ID: 24324698
[TBL] [Abstract][Full Text] [Related]
39. Enteral donor pre-treatment with ursodeoxycholic acid protects the liver against ischaemia-reperfusion injury in rats.
Nowak G; Norén UG; Wernerson A; Marschall HU; Möller L; Ericzon BG
Transpl Int; 2005 May; 17(12):804-9. PubMed ID: 15815896
[TBL] [Abstract][Full Text] [Related]
40. Activation of Trpv4 reduces the hyperproliferative phenotype of cystic cholangiocytes from an animal model of ARPKD.
Gradilone SA; Masyuk TV; Huang BQ; Banales JM; Lehmann GL; Radtke BN; Stroope A; Masyuk AI; Splinter PL; LaRusso NF
Gastroenterology; 2010 Jul; 139(1):304-14.e2. PubMed ID: 20399209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
